# Glucopyranosyl sulfates as modulators of the complement system.

## Abstract
Novel compounds of the formula

## Claims
WE CLAIM 1. A compound of the formula EMI60.1 wherein Y isEMI60.2 orEMI60.3 X is SO3M and M is a nontoxic pharmaceutically acceptable cation salt, wherein the salt forming moiety is alkali metal, alkaline earth metal, aluminum, ammonia or substituted ammonia consisting of trialkylamine C1 C6 , piperidine, pyrazine, alkanolamine C2 C6 or cycloalkylamine C3 C6 A is S or O B is NHCO , NHSO2 , NHCH2 or NH R is CH2OSO3M, COOCH3 or COOM and Z is CO or a straight or branched chain alkylidene group CH2 m , where m is an integer 0 12, inclusive, with the proviso that when m is zero or one, B cannot be NHSO2 . 2. The compound according to Claim 1, tetradecasodium N,N bis 4 2,3,6 tri O sulfo 4 O 2,3,4,6 tetra O sulfo a D glucopyranosyl ss D glucopyranosylthio phenyl octanediamide tetradecasodium N,N bis 4 2,3,6 tri 0 sul fo 4 0 2,3,4,6 tetra 0 sulfo a D glucopyranosyl ss D glu copyranosylthio phenyl butanediamide tetradecasodium N,N bis 4 2,3,6 tri O sulfo 4 O 2,3,4,6 tetra O sulfo alpha a glucopyranosyl ss D glucopyranosylthio phenyl pentane diamide tetradecasodium N,N bis 4 2,3,6 tri 0 sulfo 4 0 2,3,4,6 tetra 0 sulfo a glucopyranosyl ss glucopy ranosylthio phenyl hexanediamide tetradecasodium N,N bis 4 2,3,6 tri O sulfo 4 O 2,3,4,6 tetra O sulfo alpha D gluco pyranosyl ss D glucopyranosylthio phenyl heptanediamide tetradecasodium N,N bis 4 2,3,6 tri 0 sulfo 4 0 2,3,4,6 tetra O sulfo a D glucopyranosyl D glucopyranosylthiol phenyl decanediamide tetradecasodium N,N bis 4 2,3,6 tri O sulfo 4 0 2,3,4,6 tetra 0 sulfo a D glucopyranosyl ss D glucopyranosylthio phenyl propanediamide tetradecasodium N,N bis 4 2,3,6 tri O sulfo 4 O 2,3,4,6 tetra O sulfo ss D glucopyranosyl ss D glucopyranosylthio phenyl pentanediamide tetradecasodium N,N bis 4 2,3,6 tri O sulfo 4 0 2,3,4,6 tetra 0 sulfo a D glucopyranosyl ss glucopyranosylthio phenyl tetradecanediamide tetradecasodium N,N bis 4 2,3,6 tri O sulfo 4 O 2,3,4,6 tetra O sulfo a D glucopyranosyl ss D glucopyranosylthio phenyl ethanediamide tetradecasodium N,N bis 4 2,3,6 tri O sulfo 4 0 2,3,4,6 tetra 0 sulfo a D glucopyranosyl ss D glucopyranosylthio phenyl butanediamine tetradecatriethylammonium N,N bis 4 2,3,6 tri O sulfo 4 O 2,3,4,6 tetra O sulfo a D glucopyranosyl ss glucopyranosylthio phenyl octanediamide tetradecatriethylammonium N,N bis 4 2,3,6 tri O sulfo 4 0 2,3,4,6 tetra 0 sulfo a D glucopyranosyl ss glucopyranosylthio phenyl butanediamide tetradecatriethylammonium N,N bis 4 2,3,6 tri O sulfo 4 O 2,3,4,6 tetra O sulfo a D glucopyranosyl ss D glucopyranosylthio phenyl pentanediamide tetradecatriethylammonium N,N bis 4 2,3,6 tri O sulfo 4 O 2,3,4,6 tetra O sulfo alpha D gluco pyranosyl ss D glucopyranosylthio phenyl hexanediamide tetradecatriethylammonium N,Nt bist4 2,3,6 tri O sulfo 4 0 2,3,4,6 tetra 0 sulfo a glucopyranosyl ss D glucopy ranosylthiojphenyl Iheptanediamide tetradecatriethylammonium N,N bis 4 2,3,6 tri O sulfo 4 O 2,3,4,6 tetra O sulfo alpha D glucopyranosyl ss D glucopyranosyl thio phenyl decanediamide tetradecatriethylammonium N,N bis 4 2,3,6 tri O sulfo 4 O 2,3,4,6 tetra O sulfo alpha D glucopyranosyl ss D glucopyranosylthio phenyl propanediamide tetradecatriethylammonium N,N bis 4 2,3,6 tri O sulfo 4 O 2,3,4,6 tetra O sulfo alpha D glucopyranosyl ss D glucopyranosyl phenyl tetradecanediamide tetradecatriethylammonium N,N bis 4 2,3,6 tri O sulfo 4 O 2,3,4,6 tetra O sulfo alpha D glucopyranosyl ss D glucopyranosylthiolphenyllethanedi amide tetradecatriethylammonium N,N bis 4 2,3,6 tri Osulfo 4 O 2,3,4,6 tetra O sulfo ss D glucopyranosyl ss D glucopyranosylthio phenyl pentadiamide tetradecatriethylammonium N,N bis 4 2,3,6 tri O sulfo O 2,3,4,6 tetra O sulfo a D glucopyranosyl i3 D glucopyranosyltbioj phenyl butanediamine tetradecasodium N,N bis 4 2,3,6 tri O sulfo 4 0 2,3,4,6 tetra 0 sulfo a glucopyranosyl ss D glucopyranosyloxy phenyl butanediamide tetradecasodium N,N bis 4 2,3,6 tri O sulfo 4 O 2,3,4,6 tetra O sulfo a glucopyranosyl ss glucopyranosyloxy3phenyll butanediamine tetradecatriethylammonium N,N bis 4 2,3,6 tri O sulfo 4 0 2,3,4,6 tetra 0 sulfo a glucopyranosyl ss D glucopyranosyloxy phenyl butanediamide tetradecatriethylammonium N,N bis 4 2,3,6 tri O sulfo 4 O 2,3,4,6 tetra O sulfo a D glucopyranosyl I3 D glucopyranosyloxy phenyl butanediamine octasodium N,N bis 4 2,3,4,6 tetra O sulfo ss D glucopyranosyl thio phenyl pentadiamide hexasodium 1,4 dioxo 1,4 butanediyl bistimino 4,1 phenyl enembis 2,3,4 tri 0 sulfo 1 thio ss glucopyranosiduronic acid , dimethyl ester octasodium l,5 dioxo l,5 pentane diyl bis imino 4,1 phenylene bis 2,3,4 tri O sulfo 1 thio ss D glucopyranosiduronic acid octatriethylammonium N,N bis 4 2,3,4,6 tetra O sulfo ss D glucopyranosyl thio phenyl pentanediamide hexatriethylammonium 1,4 dioxo 1,4 butanediyl bis imino 4,1 phenylene bis 2,3,4 tri 0 sulfo l tbio B B glucopyranosiduronic acid , dimethyl ester octatriethylammonium 1,5 dioxo 1,5 pentanediyl bis imino 4,1 phenylene bis 2,3,4 tri O sulfo 1 thio ss D glucopyranosiduronic acid tetradecatriethylammonium N,N bis 4 2,3,6 tri O sulfo 4 O 2,3,4,6 tetra O sulfo alpha D gluco pyranosyl ss D glucopyranosyl thio phenyl urea or tetradecasodium N,N bis 4 2,3,6 tri 0 sulfo 4 0 2,3,4,6 tetra O sulfo a D glucopyranosyl ss D glucopyranosyllthio phenyl urea. 3. A process of preparing a compound of the formula EMI63.1 wherein Y isEMI63.2 orEMI63.3 X is SO3M and M is a nontoxic pharmaceutically acceptable cation salt, wherein the salt forming moiety is alkali metal, alkaline earth metal, aluminum, ammonia or substituted ammonia consisting of trialkylamine C1 C , piperidine, pyrazine, alkanolamine C2 C6 or cycloalkylamine C3 C6 A is S or 0 B is NHCO , NHSO2 , NHCH2 or NH R is CH20S03M, COOCH3 or COOM and Z is CO or a straight or branched chain alkylidene group CH2 m , where m is an integer 0 12, inclusive, with the proviso that when m is zero or one, B cannot be NHSO2 , which comprises A reacting 4 aminothiophenyl in dimethoxyethane and sodium hydride in oil with a solution of acetobromo a D maltose or cellobiose in dimethoxyethane, under an inert atmosphere, for several hours, subjecting the mother liquor to dry column chromatography on silica gel us ing the solvent system ethyl acetate hexane 1 1 giving 4 aminophenyl 2,3,6 tri 0 acetyl 4 O 2,3,4,6 tetra O acetyl alpha or ss D glucopyranosyl l thio a or ss D glucopyranoside then reacting with an appropriate acid chloride of the formula X CH2 m X, where X is COC1 or S02C1 and m is an integer 0 12 with the proviso that when m is zero or one X cannot be S02C1 , in dry pyridine acetonitrile 1 1 under an inert atmosphere for 18 36 hours, extracting from a suitable organic solvent, giving a compound of the formula EMI64.1 alpha or ss where B and Z are as hereinabove defined, treating this acetylatedderivative in ammonia saturated methanol at OOC, or sodium in methanol, for 18 24 hours extracting from absolute ethanol, giving the corresponding deacetylated derivative of the formula EMI65.1 where B and Z are as hereinabove defined, then converting to the tetradecatriethylammonium sulfate derivatives of the formula EMI65.2 where B and Z are as hereinabove defined and Y is NH C2H5 3, by treating with triethylamine sulfur trioxide complex inN,N dimethylacetamide, under an inert atmosphere at 60 659C, for several hours reacting with a cation containing compound wherein the salt forming moiety is selected from the group consisting of alkali metal, alkaline earth metal, aluminum, ammonia and substituted ammonia selected from the group consisting of piperidine, pyrazine, alkanolamine C2 C6 and cycloalkylamine C3 C6 , and thereafter precipitating in ethanol, giving the desired products or B reacting sodium 4 nitrophenol and potassium hydroxide with a solution of acetobromo a D maltose or cellobiose in aqueous acetone for several hours, then reducing the resultant product in a hydrogen atmosphere in the presence of palladium on carbon and acetic acid as solvent, giving 4 aminophenyl 2,3,6 tri O acetyl 4 O 2,3,4,6 tetra O acetyl alpha or ss D glucopyranosyl ator f3 D glucopyranoside reacting with an appropriate acid chloride of the formula X CH2 m X, where X is COCl or SO2Cl and m is an integer 0 12 with the proviso that when m is zero or one, X cannot be S02C1 , in dry pyridine acetonitrile 1 1 under an inert atmosphere for 18 36 hours extracting from a suitable organic solvent, giving a compound of the formula EMI66.1 where B and Z are as hereinabove defined treating this acetylated derivative in ammonia saturated methanol at OOC, or sodium in methanol, for 18 24 hours giving the corresponding deacetylated derivative of the formula EMI66.2 where B and Z are as hereinabove defined then converting to the tetradecatriethylammonium sulfate derivative of the formula EMI67.1 where Y is NH C2H5 3, by treating with triethylamine sulfur trioxide complex in N,N dimethylacetamide, under an inert atmosphere at 60 650C, for several hours reacting with a cation containing compound wherein the salt forming moiety is selected from the group consisting of alkali metal, alkaline earth metal, aluminum, ammonia and substituted ammonia selected from the group consisting of piperidine, pyrazine, alkanolamine C2 C6 and cycloalkylamine C3 C6 , and thereafter precipitating in ethanol, giving the desired Products or C either reacting a mixture of sodium hydride in oil dispersion in a solvent such as dimethoxyethane under an inert atmosphere with a solution of aminothiophenol in dimethoxyethane stirring for 3.5 hours adding a solution of a bromoacetyl pyranoside in dimethoxyethane stirring overnight giving 4 aminophenylthio 2,3,4,6 tetra 0 acetyl a or ss glucopyranoside derivative or alternatively, reacting a mixture of sodium hydride in oil dispersion in a solvent such as dimethoxyethane under an inert atmosphere with a solution of sodium aminothiophenol in dimethoxyethane stirring for 2 hours adding a solution of methyl acetobromoglucuronate in dimethoxyethane, stirring overnight giving 4 aminophenylthio 2,3,4 tri O acetyl a or B glucopyranosiduronic acid, methyl ester derivative then reacting either 4 aminophenylthio 2,3,4,6 tetra 0 ace tyl a or ss D glucopyranoside or 4 aminophenylthio 2,3,4 tri O acetyl aCor ss glucopyranosiduronic acid, methyl ester with an acid chloride, for example,EMI68.1 where m is an integer 0 12 in a solvent such as acetonitrile under an inert atmosphere for 2 or 4 hours respectively reacting this acetate with ammonia saturated methanol at to 5 0C or with sodium in methanol under an inert atmosphere for 2 hours then reacting with triethylamine sulfur trioxide in N,N dimethylacetamide at 60 65 0C under an inert atmosphere for 4 hours, giving the polytriethylammonium derivative of the above formula where M is NH C2H5 3 then reacting with a cation containing compound wherein the salt forming moiety is selected from the group consisting of alkali metal, alkaline earth metal, aluminum, ammonia and substituted ammonia selected from the group consisting of piperidine, pyrazine, alkanolamine C2 C6 and cycloalkylamine C3 C6 , and precipitating in ethanol, giving the final products or D reacting a 4 aminophenyl 2,3,6 tri 0 acetyl 4 0 2,3,4,6 tetra 0 acetyl a or f3 D glucopyranosyl l thio a or ss D glucopyranoside with phosgene in toluene and pyridine for 15 25 hours and purifying by chromatography, giving an N,N bis 4 2,3,6 tri O acetyl 4 O C2,3,4,6 tetra O acetyl alpha or ss D glucopyranosyl alpha or ss D glucopyranosyl thio phenyllurea then reacting with methanol saturated with ammonia at 5 to 50C, giving an N,N bis 4 4 O a or ss D glucopyranosyl alpha or ss D glucopyranosyl thio phenyl urea then reacting with triethylamine sulfur trioxide in dryN,N dimethylacetamide at 60 700C for 40 60 hours giving the compounds of the above formula where M is tH C2H5 3 reacting with a cation containing compound wherein the salt forming moiety is selected from the group consisting of alkali metal, alkaline earth metal, aluminum, ammonia and substituted ammonia selected from the group consisting of piperidine, pyrazine, alkanolamine C2 C6 and cycloalkylamine C3 C6 , and thereafter precipitating in ethanol, giving the desired products. 4. A composition of matter in dosage unit form which comprises an effective complement modulating amount from about 0.5 mg to about 500 mg of a compound of the formula EMI69.1 wherein Y isEMI69.2 orEMI69.3 X is SO3M and M is a nontoxic pharmaceutically acceptable cation salt, wherein the salt forming moiety is alkali metal, alkaline earth metal, aluminum, ammonia or substituted ammonia consisting of trialkylamine C1 C6 , piperidine, pyrazine, alkanolamine C2 C6 or cycloalkylamine C3 C6 A is S or O B is NHCO , NHSO2 , NHCH2 or NH R is CH20S03M, COOCH3 or COOM and Z is CO or a straight or branched chain alkylidene group CH2 m , , where m is an integer 0 12, inclusive, with the proviso that when m is zero or one, B cannot be NHS02 . in association with a pharma ceutically acceptable carrier. 5. The composition of matter according to Claim 4, wherein the compound is tetradecasodium N,N bis 4 2,3,6 tri O sulfo 4 O 2, 3,4,6 tetra O sulfo alpha D glucopyranosyl ss D glucopyranosyl thio phenyl octanediamide tetradecasodium N,N bis 4 2,3,6 tri O sul fo 4 0 2,3,4,6 tetra 0 sulfo a glucopyranosyl ss glu copyranosylthio phenyl butanediamide tetradecasodium N,N bis 4 2,3,6 tri O sulfo 4 O 2,3,4,6 tetra O sulfo alpha glucopyranosyl ss glucopyranosylthio phenyl pentane diamide tetradecasodium N,N bis 4 2,3,6 tri O sulfo 4 0 2,3,4,6 tetra 0 sulfo a glucopyranosyl ss glucopy ranosylthio phenyl hexanediamide tetradecasodium N,N bis 4 2,3,6 tri O sulfo 4 O 2,3,4,6 tetra O sulfo alpha D gluco pyranosyl ss D glucopyranosylthio phenyl heptanediamide tetradecasodium N,N bis 4 2,3,6 tri 0 sulfo 4 0 2,3,4,6 tetra O sulfo a D glucopyranosyl D glucopyranosylthio phenyl decanediamide tetradecasodium N,N bis 4 2,3,6 tri O sulfo 4 0 2,3,4,6 tetra 0 sulfo a glucopyranosyl ss D glucopyranosylthio phenyl propanediamide tetradecasodium N,N bis 4 2,3,6 tri O sulfo 4 O 2,3,4,6 tetra O sulfo ss D glucopyranosyl ss glucopyranosylthio phenyl pentanediamide tetradecasodium N,N bis 4 2,3,6 tri O sulfo 4 0 2,3,4,6 tetra 0 sulfo a glucopyranosyl ss glucopyranosylthio phenyl jtetradecanediamide tetradecasodium N,N bis 4 2,3,6 tri O sulfo 4 O 2,3,4,6 tetra O sulfo a D glucopyranosyl ss glucopyranosylthio phenyl ethanediamide tetradecasodium N,N bis 4 2,3,6 tri O sulfo 4 0 2,3,4,6 tetra 0 sulfo a glucopyranosyl ss glucopyranosylthio phenyl butanediamine tetradecatriethylammonium N,N bis 4 2,3,6 tri O sulfo 4 O 2,3,4,6 tetra O sulfo a glucopyranosyl ss D glucopyranosylthio phenyl octanediamide tetradecatriethylammonium N,N bis 4 2,3,6 tri O sulfo 4 0 2,3,4,6 tetra 0 sulfo a D glucopyranosyl ss D glucopyranosylthio phenyl butanediamide tetradecatriethylammonium N,N bis 4 2,3,6 tri O sulfo 4 O 2,3,4,6 tetra O sulfo a D glucopyranosyl D glucopyranosylthio phenyl pentadiamide tetradecatriethylammonium N,N bis 4 2,3,6 tri O sulfo 4 O 2,3,4,6 tetra O sulfo alpha D gluco pyranosyl ss D glucopyranosylthio phenyl hexanediamide tetradecatriethylammonium N,N bis 4 2,3,6 tri O sulfo 4 0 2,3,4,6 tetra 0 sulfo a D glucopyranosyl ss D glucopy ranosylthio phenyl heptanediamide tetradecatriethylammonium N,N bis 4 2,3,6 tri O sulfo 4 O 2,3,4,6 tetra O sulfo a D glucopyranosyl ss D glucopyranosyl thio phenyl decanediamide tetradecatriethylammonium N,N bis 4 2,3,6 tri O sulfo 4 0 2,3,4,6 tetra 0 sulfo a D glucopyranosyl ss D glucopyranosylthio phenyl propanediamide tetradecatriethylammonium N,N bis 4 2,3,6 tri O sulfo 4 O 2,3,4,6 tetra O sulfo a D glucopyranosyl ss D glucopyranosylthio phenyl tetradecanediamide tetradecatriethylammonium N,N bis 4 2,3,6 tri O sulfo 4 O 2,3,4,6 tetra O sulfo alpha D glucopyranosyl ss D glucopyranosylthio phenyl ethanediamide tetradecatriethylammonium N,N bis 4 2,3,6 tri O sulfo 4 0 2,3,4,6 tetra 0 sulfo ss D glucopyranosyl ss D glucopyranosylthio phenyl pentenediamide tetradecatriethylammonium N,N bis 4 2,3,6 tri 0 sulfo 4 0 2,3,4,6 tetra O sulfo a D glucopyranosyl ss D glucopyranosylthio phenyl butanediamine tetradecasodium N,N bis 4 2,3,6 tri O sulfo 4 0 2,3,4,6 tetra 0 sulfo a D glucopyranosyl ss D glucopyranosyloxy phenyl butanediamide tetradecasodium N,N , bis 4 2,3,6 tri O sulfo 4 O 2,3,4,6 tetra O sulfo a D glucopyranosyl t3 D glucopyranosyloxyjphenyli butanediamine tetradecatriethylammonium N,N bis 4 2,3,6 tri O sulfo 4 0 2,3,4,6 tetra 0 sulfo a D glucopyranosyl ss D glucopyranosyloxy phenyl butanediamide tetradecatriethylammonium N,N bis 4 2,3,6 tri 0 sulfo 4 0 2,3,4,6 tetra O sulfo a D glucopyranosyl D glucopyranosyloxy phenyl butanediamine octasodium N,N bis 4 2,3,4,6 tetra O sulfo ss D glucopyranosyl thio phenyl pentanediamide hexasodium 1,4 dioxo 1,4 butanediyl bis imino 4,1 phenyl ene bis 2S3f4 tri o sulfo l thio ss D glucopyranosiduronic acid , dimethyl ester octasodium 1,5 dioxo 1,5 pentane diyl bis imino 4,1 phenylene bis 2,3,4 tri 0 sulfo 1 thio ss D glucopyranosiduronic acid octatriethylammonium N,N bis 4 2,3,4,6 tetra O sulfo ss D glucopyranosyl thio phenyl pentanediamide hexatriethylmethylammonium 1,4 dioxo 1,4 butanediyl bis imino 4,1 phenylene bis 2,3,4 tri 0 sulfo l thio B p glucopyranosiduronic acid , dimethyl ester octatriethylammonium 1,5 dioxo 1,5 pentanediyl bis imino 4,1 phenylene bis 2,3,4 tri 0 sulfo 1 thio ss glucopyrano siduronic acid tetradecatriethylammonium N,N bist4 2,3,6 tri O sulfo 4 O 2,3,4,6 tetra O sulfo alpha D gluco pyranosyl ss D glucopyranosyl thio phenyl urea or tetradecasodium N,N bis 4 2,3,6 tri O sulfo 4 O 2,3,4,6 tetra O sulfo a D glucopyranosyl ss glucopyranosyl thio phenyl urea. 6. A compound of the formula EMI72.1 wherein Y isEMI72.2 orEMI73.1 W is H or COCH3 R is CH20W COOH or COOCH3 A is Sor 0 B is NHCO , NHSO2 , NHCH2 or NH and Z is CO or a straight or branched chain alkylidene group CH2 m , where m is an integer 0 12, inclusive, with the proviso that when m is zero or one, B cannot be NHS02 . 7. A dental preparation characterized in that said preparation contains as a topically effective, therapeutically active ingredient a compound of the formula EMI73.2 wherein Y isEMI73.3 orEMI73.4 X is SO3M and M is a nontoxic pharmaceutically acceptable cation salt, wherein the salt forming moiety is alkali metal, alkaline earth metal, aluminum, ammonia or substituted ammonia consisting of trialkylamine C1 C6 , piperidine, pyrazine, alkanolamine C2 C6 or cycloalkylamine C3 C6 A is S or 0 B is NHCO , NHSO2 , NHCH2 or NH R is CH20S03M, COOCH3 or COOM and Z is CO or a straight or branched chain alkylidene group CH2 m , where m is an integer 0 12, inclusive, with the proviso that when m is zero or one, B cannot be NHSO2 .

## Description
TITLE MODULATORS OF THE COMPLEMENT SYSTEM This invention relates to novel compounds of the following formula EMI1.1 wherein Y isEMI1.2 orEMI1.3 X is SO3M and M is a nontoxic pharmaceutically acceptable cation salt, wherein the salt forming moiety is alkali metal, alkaline earth metal, aluminum, ammonia or substituted ammonia consisting of trialkylamine C1 C6 , piperidine, pyrazine, alkanolamine C2 C6 or cycloalkylamine C3 C6 A is S or O B is NHCO , NHSO2 , NHCH2 or NH R is CH2OSO3M, COOCH3 or COOM and Z is CO or a straight or branched chain alkylidene group CH2 m , where m is an integer 0 12, inclusive, with the proviso that when m is zero or one, B cannot be NHSO2 , which compounds are highly active as complement modulators. Although the compounds of Formula I are shown as being fully sulfated, this invention contemplates partially sulfated ptoducts. The invention further relates to novel compounds of the following formula EMI2.1 wherein Y isEMI2.2 orEMI3.1 A, B and Z are as described in Formula I W is H or COCH3 and R is CH2OW COOH or COOCH3 In the above Formulas I and II the invention is intended to include disaccharides consisting of aldohexoses, ketohexoses, aldopentoses and the like as well as oligosaccharides wherein the sugar units are 2 8 consisting of maltotrioses, maltotetraoses, maltopentaoses and the like. The term complement refers to a complex group of proteins in body fluids that, working together with antibodies or other factors, play an important role as mediators of immune, allergic, immunochemical and or immunopathological reactions. The reactions in which complement participates take place in blood serum or in other body fluids, and hence are considered to be humoral reactions. With regard to human blood, there are at present more than 20 proteins in the complement system consisting of the so called classical and alternative pathways. These complement proteins are generally designated by the letterC and by number C1, C2, C3 and so on up to C9. The complement protein C1 is actually an assembly of subunits designated Clq, Clr and Cls. The numbers assigned to the complement proteins reflect the sequence in which they become active, with the exception of complement proteinC4, which reacts after C1 and before C2. The numerical assignments for the proteins in the complement system were made before the reaction sequence was fully understood. A more detailed discussion of the complement system and its biochemical, biological and pathological role in the body processes can be found in, for example, Bull. W.H. 0. 39 935 1968 Annu. Rev. Med. 19 1 1968 Johns Hopkins Med. J. 128 57 1971 Harvey Lect. 66 75 1972 N.Engl. J. Med. 287 452, 489, 545, 592, 642 1972 Sci.Am. 229 5 54 1973 Fed. Pro. 32 134 1973 Med.World, October 11, 1974, p. 53 J. Allergy Ciin. Immunol.53 298 1974 Cold Spring Harbor Conf. CellProliferation 2 Proteases Biol. Control 229 1975 Annu. Rev. Biochem. 44 697 1975 Complement inClinical Medicine, Dis. Mon. 1975 Complement, Scope,December 1975 Ann. Intern. Med. 84 580 1976 Transplant Rev. 32 1976 Complement Mechanisms andFunctions, Prentice Hall, Englewood Cliffs, N. J. 1976 Essays Med. Biochem. 2 1 1976 Hosp. Pract. 12 33 1977 Perturbation of Complement in Disease, Chap. 15 inBiol. Amplification Systems in Immunol. Ed. Day and Good , Plenum, New York and London 1977 Am. J. Clin.Pathol. 68 647 1977 Biochem. Soc. Trans. 5 1659 1977 Harvey Lect. 72 139 1976 1977 J. Periodontol.48 505 1977 Biochem. Soc. Trans. 6 798 1978 Clin. and Exp. Dermatol. 4 271 1979 Infect. Dis. Rev.1 483 1979 . The complement system e.g., classical pathway can be considered to consist of three subsystems 1 a recognition unit Clq which enables it to combine with antibody molecules that have detected a foreign invader 2 an activation unit Clr, Cls, C2, C4, C3 which prepares a site on the neighboring membrane and 3 an attack unit C5, C6, C7. C8 and C9 which creates a hole in the membrane. The membrane attack unit is nonspecific it destroys invaders only because it is generated in their neighborhood. In order to minimize damage to the host s own cells, its activity must be limited in time. This limitation is accomplished partly by the spontaneous decay of activated complement and partly by interference by inhibitors and destructive enzymes.The control of complement, however, is not perfect, and there are times when damage is done to hosts cells. Immunity is, therefore, a double edged sword. Activation of the complement system also accelerates blood clotting. This action comes about by way of the complement mediated release of a clotting factor from platelets. The biologically active complement fragments and complexes can become involved in reactions that damage the host s cells. These pathogenic reactions can result in the development of immune complex diseases. For example, in some forms of nephritis, complement damages the basal membrane of the kidney, resulting in the escape of protein from the blood into the urine. The disease disseminated lupus erythematosus belongs in this category its symptoms include nephritis, visceral lesions and skin eruptions. The treatment of diphtheria or tetanus with the injection of large amounts of antitoxin sometimes results in serum sickness, an immune complex disease.Rheumatoid arthritis also involves immune complexes. Like disseminated lupus erythematosus, it is an autoimmune disease in which the disease symptoms are caused by pathological effects of the immune system in the host s tissues. In summary, the complement system has been shown to be involved with inflammation, coagulation, fibrinolysis, antibody antigen reactions and other metabolic processes. In the presence of antibody antigen complexes the complement proteins are involved in a series of reactions which may lead to irreversible membrane damage if they occur in the vicinity of biological membranes.Thus, while complement constitutes a part of the body s defense mechanism against infection it also results in inflammation and tissue damage in the immunopatholoqical process. The nature of certain complement proteins, suggestions regarding the mode of complement binding to biological membranes and the manner in which complement effects membrane damage are discussed in Annu. Rev.Biochem. 38 389 1969 J. Exp. Med. 141 724 1975 J. Immunol. 116 1431 1976 119 1, 1195, 1358, 1482 1977 120 1841 1978 Immunochemistry 115 813 1978 J. Biol. Chem. 254 9908 1979 . A variety of substances have been disclosed as inhibiting the complement system, ifs., as complement inhibitors. For example, the compounds, 3,3 ureylenebis 6 2 amino 8 hydroxy 6 sulfo 1 naphthylazo benzenesulfonic acid , tetrasodium salt chlorazol fast pink , heparin and a sulphated dextran have been reported to have an anticomplementary effect, Br. J. Exp. Pathol. 33 327 1952 .German Patent No. 2,254,893 or South African PatentNo. 727,923 discloses certain l diphenylmethyl 4 3phenylallyl piperazines useful as complement inhibitors.Other chemical compounds having complement inhibiting activity are disclosed in, for example, J. Med. Chem. 12 415, 902, 1049, 1053 1969 Can. J. Biochem. 47 547 1969 J. Immunol. 104 279 1970 J. Immunol. 106 241 1971 J. Immunol. 111 1061 1973 Biochim.Biophys. Acta 317 539 1973 Life Sci. 13 351 1973 J. Immunol. 113 584 1974 Immunology 26 819 1974 J. Med. Chem. 17 1160 1974 Biochim. Biophys. Res.Comm. 67 225 1975 Ann. N. Y. Acad. Sci. 256 441 1975 J. Med. Chem. 19 634, 1079 1976 J. Immunol.118 466 1977 Arch. Int. Pharmacodyn. 226 281 1977 Biochem. Pharmacol. 26 325 1977 J. Pharm. Sci. 66 1367 1977 Chem. Pharm. Bull. 25 1202 1977 Biochim.Biophys. Acta 484 417. 1977 J. Clin. Microbiol. 5 278 1977 Immunochemistry 15 231 1978 Immunology 34 509 1978 J. Exp. Med. 147 409 1978 Thromb.Res. 14 179 1979 J. Immunol. 122 2418 1979 J.Chem. Soc. Chem. Comm. 726 1979 Immunology 36 131 1979 Biochim. Biophys. Acta 611 196 1980 and J.Med. Chem. 23 240 1980 . It has been reported that the known complement inhibitors, epsilon aminocaproic acid and tranexamic acid, have been used with success in the treatment of hereditary angioneurotic edema, a disease state resulting from an inherited deficiency or lack of function of the serum inhibitor of the activated first component of complement C1 inhibitor , N. Engl. J. Med. 286 808 1972 287 452 1972 Ann. Intern. Med. 84 580 1976 J. AllergyClin. Immunol. 60 38 1977 . Also androgenic steroids have been used successfully in the treatment of this physiological disorder see Medicine 58 321 1979 Arthritis Rheum. 22 1295 1979 Am. J. Med. 66 681 1979 and J. Allergy Clin. Immunol. 65 75 1980 . It has also been reported that the drug pentosan polysulfoester has an anticomplementary activity on human serum, both in vitro and in vivo, as judged by the reduction in total hemolytic complement activity, Pathol.Biol. 25 33 25 2 105 25 3 179 1977 . The compounds of Formula I find utility as complemene modulators in body fluids and as such may be used to ameliorate or prevent those pathological reactions requiring the function of complement and in the therapeutic treatment of warm blooded animals having immunologic diseases such as rheumatoid arthritis, systemic lupus erythematosus, certain kinds of glomerulonephritis, certain kinds of autoallergic hemolytic anemia, certain kinds of platelet disorders and certain kinds of vasculitis. These compounds may also be used in the therapeutic treatment of warm blooded animals having nonimmunologic diseases such as paroxysmal nocturnal hemoglobinurea, hereditary angioneurotic edema and inflammatory states induced by the action of bacterial or lysosomal enzymes on the appropriate complement components as, for example, inflammation following coronary occlusion.They also may be useful in the treatment of transplant rejection and ulcers and as blood culture and transport mediums. The sulfated compounds of this invention such as the sodium and aluminum salts1 may be particularly useful in the treatment of ulcers and the like on oral therapy. Also, the non sulfated intermediate compounds of Formula II may be useful as immuno enhancing agents or potentiators. The novel compounds of this invention may be prepared according to the following flowcharts. FLOWCHART AEMI9.1 FLOWCHART A continued EMI10.1 FLOWCHART A continued EMI11.1 In accordance with the above Flowchart A, a brominated peracetyl sugar 1 is reacted with a p nitrothio phenol 2 , and sodium hydride in a solvent such as dimethoxyethane under an inert atmosphere for several hours, giving a 4 nitrophenyl 2,3,6 tri O acetyl 4 O 2,3,4,6 tetra O acetyl a or D glucopyranosyl l thio a or ss D glucopyranoside 3 which is then catalytically reduced to the corresponding 4 aminophenyl derivative 4 .Alternatively, similar reaction of 1 with p aminothio phenol 5 produces 4 directly without requiring reduction. The derivative 4 is then treated with an acid chloride 6 where X is, for example, COC1 or SO2C1 Z is CH2 m and m is an integer 0 12 in a solvent such as acetonitrile under an inert atmosphere for several hours giving a N,N bis 4 2,3,6 tri O acetyl 4 O 2,3,4,6 tetra O acetyl a or D glucopyranosyl a or ss D glucopyrano sylthiolphenyllalkyldiamide 7 , where Z is as described above and B is, for example, NHCO .The derivative 7 is then reacted with ammonia saturated methanol at 5 to 50C under an inert atmosphere or with sodium in methanol for several hours giving a N,Nt bis 4 4 O a or a D glu copyranosyl a or a D glucopyranosylthio phenyl alkyldi amide 8 where B and Z are as described above. The derivative 7 may also be reduced with diborane in dry tetrahydrofuran under an inert atmosphere at 5 to 50C, giving the derivative 8 where Z is as described above and B is NHCH2 . Derivative 8 is then reacted with triethylamine sulfur trioxide complex in N,N dimethylacetamide, under an inert atmosphere at 60 650C for several hours, giving the tetradecatriethylammonium derivative 9 , where Y isNH C2H5 3 which is then, if desired, reacted with a cationcontaining compound wherein the salt forming moiety is selected from the group consisting of alkali metal, alkaline earth metal, aluminum, ammonia and substituted ammonia selected from the group consisting of piperidine, pyrazine, alkanolamine C2 C6 and cycloalkylamine C3 C6 , and thereafter precipitated in ethanol, giving the end product 10 of this invention. FLOWCHART BEMI13.1 FLOWCHART B continued EMI14.1 FLOWCHART B continued EMI15.1 In accordance with the above Flowchart B, a bromoacetyl pyranoside 1 where R is CH2OCQCH3 or COOCH3I is reacted with a g nitrothio or oxy phenyl 2 where A is Sor O 1 and sodium hydride in a solvent such as dimethoxyethane, under an inert atmosphere for several hours, giving a 4 nitrophenyl 2,3,4 tri O acetyl or ss D glucopyranosyl l thio or oxy derivative 3 which is then catalytically reduced to the corresponding 4 aminophenyl derivative 4 .Alternatively, similar reaction of 1 with p aminothiophenol 5 produces 4 directly without requiring reduction. The derivative 4 is then treated with an acid chloride 6 where X is COC1 or SO2C1 Z is CH2 m and m is an integer 0 12 in a solvent such as acetonitrile under an inert atmosphere for several hours, giving a N,N bis 4 2,3,4tri O acetyl a or ss D glucopyranosyl thio or oxy phenyl alkyldiamide or alkylsulfonamide 7 where Z is as described above and B is NHCO or NHSO2 1. The derivative 7 is then reacted with ammonia saturated methanol at 5 to 50C under an inert atmosphere or with sodium in methanol for several hours, giving N,N bis 4 a or B B glucopyranosyl thio or oxy phenyl alkyldiamide or alkylsulfonamide 8 .Derivative 8 is then reacted with triethylamine sulfur trioxide complex in N,N dimethylacetamide, under an inert atmosphere at 60 650C for several hours, giving the poly triethylammonium derivative 9 where Y is S03 NH C2H5 3 , which is then, if desired, reacted with a cationcontaining compound wherein the salt forming moiety is selected from the group consisting of alkali metal, alkaline earth metal, aluminum, ammonia and substituted ammonia selected from the group consisting of piperidine, pyrazine, alkanolamine C2 C6 and cycloalkylamine C3 C6 , and thereafter precipitated in ethanol, giving the end product 10 where M is as described in the above Formula I . FLOWCHART CEMI17.1 FLOWCHART C continued EMI18.1 In accordance with the above Flowchart C, an acetobromomaltose 1 is reacted with 4 aminothiopbenol 2 and sodium hydride in a solvent such as tetrahydrofuran at reflux for 10 20 hours, giving 4 aminophenyl 2,3,6 tri O acetyl 4 O 2,3,4,6 tetra O acetyl alpha or ss D glucopyranosyl l thio a or ss D glucopyranoside 3 , which is then reacted with phosgene in a mixture of toluene and pyridine for 15 25 hours then purified by chromatography, givingN,N bis 4 2,3,6 tri O acetyl 4 O 2,3,4,6 tetra O ace tyl alpha or ss D glucopyranosyl alpha or ss glucopyranosyl thio phenyl urea 4 , which is then reacted with methanol saturated with ammonia at 5 to 50C, giving N,Nt bis 4 4 O alpha or ss D glucopyranosyl alpha or ss D glucopyra nosyl thio phenyl urea 5 , which is then reacted with triethylamine sulfur trioxide in dry N,N dimethylacetamide at 60 700C for 40 60 hours giving 6 , where X is So3ÂµH C2Hs 3, which is then, if desired, reacted with a cation containing compound wherein the salt forming moiety is selected from the group consisting of alkali metal, alkaline earth metal, aluminum, ammonia and substituted ammonia selected from the group consisting of piperidine, pyrazine, alkanolamine C2 C6 and cycloalkylamine C3 C6 , and thereafter precipitated in ethanol, giving the end product 6 of this invention. FLOWCHART DEMI20.1 FLOWCHART D continued EMI21.1 FLOWCHART D continued EMI22.1 In accordance with the above Flowchart D, a brominated peracetyl sugar 1 is reacted with sodium p nitro phenol 2 , and potassium hydroxide in a solvent such as aqueous acetone for several hours, giving a 4 nitrophenyl 2,3,6 tri O acetyl 4 O 2,3,4,6 tetra O acetyl alpha or ss D glucopyranosyl a or ss D glucopyranoside 3 which is then catalytically reduced to the corresponding 4 aminophenyl derivative 4 .The derivative 4 is then treated with an acid chloride 5 where X is, for example, COC1 or SO2C1 Z is XCH2 m ,and m is an integer 0 12 in a solvent such as acetonitrile under an inert atmosphere for several hours giving a N,N bis 4 2,3,6 tri O acetyl 4 O 2,3,4,6 tetraO acetyl a or ss D glucopyranosyl a or ss D glucopyrano syloxy phenyl alkyldiamide 6 , where Z is as described above and B is, for example, NHCO . The derivative 6 is then reacted with ammonia saturated methanol at 5 to 50C under an inert atmosphere or with sodium in methanol for several hours giving N,N bis 4 4 O a or B B gluco pyranosyl a or D glucopyranosyloxy phenylialkyldiamide 7 where B and Z are as described above.The derivative 6 may also be reduced with diborane in dry tetrahydrofuran under an inert atmosphere at 5 to 5 C, giving the derivative 7 where Z is as described above and B is NHCH2 . Derivative 7 , where Z is as described above andB is NHCO or NHCH2 , is then reacted with triethylaminesulfur trioxide complex in N,N dimethylacetamide, under an inert atmosphere at 60 650C for several hours, giving the t etradecatriethylammonium derivative 8 , where Y is NH C2H5 3 which is then, if desired, reacted with a cationcontaining compound wherein the salt forming moiety is selected from the group consisting of alkali metal, alkaline earth metal, aluminum, ammonia and substituted ammonia selected from the group consisting of piperidine, pyrazine, alkanolamine C2 C6 and cycloalkylamine C3 C6 , and thereafter precipitated in ethanol, giving the end product 9 of this invention. It is generally preferred that the respective product of each process step, described hereinabove, is separated and or isolated prior to its use as starting material for subsequent steps. Separation and isolation can be effected by any suitable purification procedure such as, evaporation, crystallization, column chromatography, thinlayer chromatography, distillation, etc. Also it should be appreciated that when typical reaction conditions e.g., temperatures, mole ratios, reaction times have been given, the conditions which are both above and below these specified ranges can also be used. though generally less conveniently. The term pharmaceutically acceptable salts refers to those salts of the parent compound which do not significantly or adversely affect the pharmaceutical properties e.g., toxicity, effectiveness, etc. of the parent compound. The salt forming moieties of the present invention which are pharmaceutically acceptable include the alkali metals e.g., sodium, potassium, etc. alkaline earth metals e.g., calcium, etc. aluminum ammonia and substituted ammonia selected from the group consisting of trialkylamine C1 C6 , piperidine, pyrazine, alkanolamine C2 C6 and cycloalkylamine C3 C6 . The term trialkylamine Cl C6 defines those amines having three aliphatic fully saturated hydrocarbon substituents containing 1 to 6 carbon atoms either linearly or branched. Typically, these amines are trimethylamine, triethylamine, tripropylamine, dimethylethylamine, dimethyl l propylamine, etc. The term alkanolamine C2 C6 refers to the above defined trialkylamines additionally substituted with at least one and not more than three hydrbxy groups on at least two of the alkyl hydrocarbon chains. Such amines are, for example, triethanolamine, tripropanolamine, etc. The term cycloalkylamine C3 C6 is defined as the 3 to 6 fully saturated carbocyclic moieties such as cyclopropyl, methylcyclobutyl, cyclopentyl, cyclohexyl, etc. The invention is illustrated by the followingExamples. The preferred novel compounds of this invention are described in Examples 1 55. Pharmaceutical preparations are shown in Examples 56 73. Example 1 4 Aminophenyl 2,3,6 tri O acetyl 4 O 2,3,4,6 tetra O acetyl alpha D glucopyranosyl 1 thin ss glucopyranoside A solution of 5.13 g of 4 aminothiophenol in 50 ml of dry dimethoxyethane was added dropwise, at a rapid rate, to a stirred mixture of 1.8 g of 50 sodium hydride in oil, under argon. The mixture was stirred for 3 4 hours, then a solution of 25.8 g of acetobromo a 9 maltose in 75 ml of dimethoxyethane was added dropwise, at a fast rate. The mixture was stirred for 18 hours, filtered and the filtrate concentrated to a brown oil. This oil was purified by dry column chromatography on 1300 g of silica gel, using ethyl acetate hexane 1 1 as eluant. Crystallization of the residual oil from ether gave 13.8 g of the desired product as white crystals, m.p. 147 1480C. Example 2 4 Nitrophenyl 2,3,6 tri O acetyl 4 O 2,3,4,6 tetraf O acetyl alpha D glucopyranosyl 1 thio ss D glucopyranoside A 20.2 g sample of 50 sodium hydride in oil dispersion was washed free of oil with hexane and suspended in 300 ml of dry dimethoxyethane under argon. To the stirred suspension was added dropwise a solution of 65 g of 4 nitrothiophenol in 130 ml of dimethoxyethane. After the addition of 4 nitrothiophenol, stirring was continued for one hour, then a solution of 235 g of bromoheptaacetylmaltose in 800 ml of dry dimethoxyethane was added dropwise during one half hour. After 2 hours of stirring at room temperature, excess sodium hydride was destroyed by the addition of 10 ml of acetic acid. Dimethoxyethane was evaporated under reduced pressure and the residue was partitioned between one liter of methylene chloride and 500 ml of water.The layers were separated, the water layer was extracted once more with 500 ml of methylene chloride, the organic layers were combined, washed with brine, dried with magnesium sulfate, and the solution was passed through a pad of magnesium silicate.The pad was washed thoroughly with methylene chloride and ether, the solvents were evaporated, and the residual orange foam was crystallized from 2 liters of methanol to yield 179.5 g of faintly yellow crystals, m.p. 163 1650C. Example 3 4 Aminophenyl 2,3,6 tri O acetyl 4 0 2,3,4,6 tetra O acetyl a D glucopyranosyl l thio ss D glucopyranoside To 91.3 g of 4 nitrophenyl 2,3,6 tri O acetyl 4 0 2,3,4,6 tetra O acetyl a D glucopyranosyl l thio ss glucopyranoside suspended in 200 ml of acetic acid was added 10 g of 10 palladium on charcoal catalyst in a Parr hydrogenation bottle, and this was hydrogenated on a Parr hydrogenator for 17 hours. The catalyst was filtered from the solution through diatomaceous earth and washed thoroughly with methanol. The solvents were evaporated in vacuo. The residue was dissolved in one liter of toluene and again evaporated. The residue was dissolved in methylene chloride and passed through a pad of magnesium silicate and the volume of the solution was adjusted to about 300 ml.To this was added 1.5 liters of ether and 5 g of activated charcoal, the solution was boiled for 3 minutes, the charcoal was filtered off and the solvents were again evaporated. The yellow foam was crystallized from 1.5 liters of ether to yield 69.6 g of light yellow crystals, isolated in three crops, m.p. 145 1480C. Example 4 N,N Bis 4 2,3,6 tri O acetyl 4 0 2,3,4,6 tetra acetyl a glucopyranosyl B p glucopyranosylthio phenylfoctanediamide To a stirred solution of 25 g of 4 aminophenyl 2,3, 6 tri 0 acetyl 4 0 2, 3,4,6 tetra 0 acetyl a D gluco pyranosyl l thio D glucopyranoside in 250 ml of a dry mixture of pyridine acetonitrile 1 1 was added a solution of 3.55 g of suberoyl chloride in 10 ml of acetonitrile. This mixture was allowed to stand, under argon, for 18 hours. An additional 0.2 ml of suberoyl chloride was added, the solution was allowed to stand for an additional 18 hours and was then poured into 2 liters of water. After stirring for 15 minutes, the oil was separated and extracted into 500 ml of dichloromethane. The extract was washed twice with 500 ml portions of 0.5N hydrochloric acid, then with saturated aqueous sodium chloride solution, dried and taken to dryness, giving 28 g of the desired product as a white foam. Examples 5 13 Treatment of 4 aminophenyl 2,3,6 tri 0 acetyl 4 0 2,3,4,6 tetra O acetyl a glucopyranosyl l thio ss glucopyranoside or other appropriate disaccharides, as well as the l oxy derivatives of this and other appropriate disaccharides, with other acid chlorides according to the procedure of Example 4, gave the products of Examples 5 13 as shown in the following Table I. Table I EMI28.1 Example SEP Acid SEP Chloride SEP Product tb 5 SEP Succinyl SEP N,N Bis 4 2,3,6 tri O acetyl 4 O 2,3,4,6 SEP chloride SEP tetra O acetyl alpha D glucopyraosyl ss D gluco SEP pyranosylthio phenyl butanediamide tb 6 SEP Glutaryl SEP N,N Bis 4 2,3,6 tri O acetyl 4 O 2,3,4,6 SEP chloride SEP tetra O acetyl alpha D glucopyraosyl ss D gluco SEP pyranosylthio phenyl pentanediamide tb 7 SEP Adipoyl SEP N,N Bis 4 2,3,6 tri O acetyl 4 O 2,3,4,6 SEP chloride SEP tetra O acetyl alpha D glucopyraosyl ss D gluco SEP pyranosylthio phenyl hexanediamide tb 8 SEP Pimeloyl SEP N,N Bis 4 2,3,6 tri O acetyl 4 O 2,3,4,6 SEP chloride SEP tetra O acetyl alpha D glucopyraosyl ss D gluco SEP pyranosylthio phenyl heptanediamide tb 9 SEP Sebacyl SEP N,N Bis 4 2,3,6 tri O acetyl 4 O 2,3,4,6 SEP chloride SEP tetra O acetyl alpha D glucopyraosyl ss D gluco SEP pyranosylthio phenyl decanidiamide tb 10 SEP Malonyl SEP N,N Bis 4 2,3,6 tri O acetyl 4 O 2,3,4,6 SEP chloride SEP tetra O acetyl alpha D glucopyraosyl ss D gluco SEP pyranosylthio phenyl propanediamide tb Table I continued EMI29.1 Example SEP Acid SEP Chloride SEP Product tb 11 SEP Tetradecanedioyl SEP N,N Bis 4 2,3,6 tri 0 acetyl 4 0 2,3,4,6 SEP chloride SEP tetra 0 acetyl alpha D glucopyranosyl ss D gluco SEP pyranosylthio phenyl tetradecanediamide tb 12 SEP Oxalyl SEP N,N Bis 4 2,3,6 tri 0 acetyl 4 0 2,3,4,6 SEP chloride SEP tetra 0 acetyl alpha D glucopyranosyl ss D gluco SEP pyranosylthi ohenyl ethanediamide tb 13 SEP Glutaryl SEP N,N Bis 4 2,3,6 tri 0 acetyl 4 0 2,3,4,6 SEP chloride SEP tetra 0 acetyl ss D glucopyranosyl ss D gluco SEP pyranosylthio phenyl pentanediamide tb Example 14 N,N Bist4 4 O a D glucopyranosyl ss D glucopyranoSylehio pbenyl octanediamide A 28.4 g portion of N,Nt bis 4 2,3,6 tri O ace tyl 4 0 2,3,4,6 tetra O acetyl D glucopyranosyl ss D glucopyranosylthiolphenyl octanediamide was dissolved in a 00c solution of 500 ml of methanol saturated with ammonia.The solution was allowed to stand at OOC, under an inert atmosphere, for 18 hours, then was warmed to ambient temperature and evaporated. The residue was triturated with 200 ml of absolute ethanol, filtered, washed in sequence with absolute ethanol, acetonitrile, then ether and dried in vacuo at 400C, giving 12.1 g of the desired intermediate as an amorphous solid. Examples 15 23 Treatment of the products of Examples 5 13 by the procedure of Example 14 resulted in the intermediate products of Examples 15 23, given in Table II. Table II EMI31.1 Example SEP Starting SEP Product tb SEP Material tb SEP Example tb 15 SEP 5 SEP N,N Bis 4 4 0 alpha D glucopyranosyl ss D gluco SEP pyranosylthio phenyl butanediamide tb 16 SEP 6 SEP N,N Bis 4 4 0 alpha D glucopyranosyl ss D gluco SEP pyranosylthio phenyl pentanediamide tb 17 SEP 7 SEP N,N Bis 4 4 0 alpha D glucopyranosyl ss D gluco SEP pyranosylthio phenyl hexanediamide tb 18 SEP 8 SEP N,N Bis 4 4 0 alpha D glucopyranosyl ss D gluco SEP pyranosylthio phenyl heptanediamide tb 19 SEP 9 SEP N,N Bis 4 4 0 alpha D glucopyranosyl ss D gluco SEP pyranosylthio phenyl decanediamaide tb 20 SEP 10 SEP N,N Bis 4 4 0 alpha D glucopyranosyl ss D gluco SEP pyranosylthio phenyl propanediamide tb 21 SEP 11 SEP N,N Bis 4 4 0 alpha D glucopyranosyl ss D gluco SEP pyranosylthio phenyl tetradecanediamide tb TableII continued EMI32.1 Example SEP Starting SEP Product tb SEP Material tb SEP Example tb 22 SEP 12 SEP N,N Bis 4 4 0 alpha D glucopyranosyl ss D gluco SEP pyranosylthio phenyl ethanediamide tb 23 SEP 13 SEP N,N Bis 4 4 0 ss D glucopyranaosyl ss D gluco SEP pyranosylthio phenyl pentanediamide tb Example 24 N,N Bis 4 4 0 alpha D glucopyranosyl ss D glucopyranosylthio phenyl butanediamine A 9.2 g portion of N,N bis 4 2,3,6 tri O acetyl 4 0 2,3,4,6 tetra O acetyl a D glucopyranosyl ss D gluco pyranosylthio phenyllbutanediamide in 30 ml of dry tetrahydrofuran was cooled in an ice bath.To this was added with magnetic stirring dropwise 210 ml of 1M solution of diborane in tetrahydrofuran. The solution was allowed to come to room temperature overnight and the excess diborane was decomposed by the addition of methanol. The white solid which separated during the reaction was collected by filtration and was suspended in 500 ml of methanol saturated with ammonia at OOC. The mixture was stirred overnight and the solid gradually dissolved as the temperature rose to room temperature. After evaporation of the solution, the residue was triturated in refluxing ethanol for one hour. The solid was collected by filtration and dried. 260 There was obtained 2.51 g as an off white solid, D6 250 1 H2O . Example 25 Tetradecasodium N,N bis 4 2,3,6 tri 0 sulfo 4 0 2, 3,4,6 tetra O sulfo a D glucopyranosyl 6 D glucopyranosyl thio phenyl octanediamide Into a warm solution of 91 g of triethylamine sulfur trioxide complex and 91 g of 4A molecular sieves in dryN,N dimethylacetamide was dissolved 14.9 g of N,N bis 4 4 0 alpha D glucopyranosyl ss D glucopyranosyl phen yl octanediamide. The resulting solution was allowed to stand at 60 650C in an oil bath, under argon, for 66 hours.The mixture was filtered and the filtrate poured into 3500 ml of acetone. After standing for one hour, the supernatant solution was decanted and the residual gum tetradecatriethylammonium salt was washed with three 150 ml portions of acetone. The gum was then dissolved in a solution composed of 19.7 g of anhydrous sodium acetate in 100 ml of water. This solution was added in a thin stream, with stirring, to 3500 ml of absolute ethanol, stirred for 20 minutes and then allowed to stand for 2 hours. The supernatant was siphoned from the solid which was then collected on a filter and washed repeatedly with absolute ethanol and finally with ether. Vacuum drying at 400C provided 33.6 g of the desired product as an amorphous powder. To remove residual amounts of sodium sulfate the product was redissolved in 200 ml of water and mixed with 40 ml of 1M barium acetate solution. The solution was centrifuged at 3000 rpm for 30 minutes and the cloudy supernatant was decanted and filtered through a 90S clarification filter, which in turn was washed with a small amount of water. The clear filtrate was passed through 400 g of activated Amberlitee CG 120 ion exchange resin Na form , packed into a 60 mm. ID glass column. The sample was washed off the column with distilled water and fractions containing carbohydrate were pooled. The combined fractions were evaporated to 150 ml and the title compound was precipitated with 4 liters of hot ethanol. The solid was collected and dried in vacuo at 1100C giving 23.9 g of yellow powder, al260 170 1 1.1 , H20 . Examples 26 35 Following the procedure of Example 25, the intermediates of Examples 15 24 are converted to the products of Examples 26 35 as given in Table III. Table III EMI35.1 Example SEP Intermediate SEP Product tb SEP Example tb 26 SEP 15 SEP Tetradecasodium SEP N,N bis 4 2,3,6 ti 0 sulfo 4 SEP 0 2,3,4,6 tetra 0 sulfo alpha D glucopyranosyl ss SEP D glucopyranosylthio phenyl butanediamide tb 27 SEP 16 SEP Tetradecasodium SEP N,N bis 4 2,3,6 tri 0 sulfo 4 SEP 0 2,3,4,6 tetra 0 sulfo alpha D glucopyranosyl ss SEP D glucopyranosylthio phenyl pentanediamide tb 28 SEP 17 SEP Tetradecasodium SEP N,N bis 4 2,3,6 tri 0 sulfo 4 SEP 0 2,3,4,6 tetra 0 sulfo alpha D glucopyranosyl ss SEP D glucopyranosylthio phenyl hexanediamide tb 29 SEP 18 SEP Tetradecasodium SEP N,N bis 4 2,3,6 tri 0 sulfo 4 SEP 0 2,3,4,6 tetra 0 sulfo alpha D glucopyranaosyl ss SEP D glucopyranosylthio phenyl heptanediamide tb 30 SEP 19 SEP Tetradecasodium SEP N,N bis 4 2,3,6 tri 0 sulfo 4 SEP 0 2,3,4,6 tetra 0 sulfo alpha D glucopyranosyl ss SEP D glucopyranosylthio phenyl decanediamide tb 31 SEP 20 SEP Tetradecasodium SEP N,N bis 4 2,3,6 tri 0 sulfo 4 SEP 0 2,3,4,6 tetra 0 sulfo alpha D glucopyranosyl ss SEP D glucopyranosylthio phenyl propanediamide tb Table III continued EMI36.1 Example SEP Intermediate SEP Product tb SEP Example tb 32 SEP 21 SEP Tetradecasodium SEP N,N bis 4 2,3,6 tri 0 sulfo 4 SEP 0 2,3,4,6 tetra 0 sulfo alpha D glucopyranosyl ss SEP D glucopyranosylthio phenyl tetradecanediamide tb 33 SEP 22 SEP Tetradecasodium SEP N,N bis 4 2,3,6 tri 0 sulfo 4 SEP 0 2,3,4,6 tetra 0 sulfo alpha D glucopyranosyl ss SEP D glaucopyranosylthio phenyl ethanediamide tb 34 SEP 23 SEP Tetradecasodium SEP N,N bis 4 2,3,6 tri 0 sulfo 4 SEP 0 2,3,4,6 tetra 0 sulfo ss D glucopyranosyl ss SEP D glucopyranosylthio phenyl pentanediamide tb 35 SEP 24 SEP Tetradecasodium SEP N,N bis 4 2,3,6 tri 0 sulfo 4 SEP 0 2,3,4,6 tetra 0 sulfo alpha D glucopyranosyl ss SEP D glucopyranosylthio phenyl butanediamine tb Example 36 4 Nitrophenyl 2,3,6 tri O acetyl 4 0 2,3,4,6 tetra O acetyl a glucopyranosyl ss glucopyranoside A mixture of 50 g of sodium 4 nitrophenol, 100 g of bromoheptaacetylmaltose, 1.0 g of potassium hydroxide, 60 ml of water, and 100 ml of acetone was stirred at ambient temperature for 20 hours.The reaction was diluted with 2 1 of water, the resultant oil was allowed to settle, and the aqueous layer was decanted. The oil was dissolved into 500 ml of methylene chloride, washed with saturated sodium bicarbonate solution, dried, and passed through a pad of hydrous magnesium silicate. Evaporation of the solvent left a light yellow oil which was crystallized from 450 ml methanol to yield 27.5 g of white crystals, m.p. 165 1700C. Example 37 4 Aminophenyl 2,3, 6 tri 0 acetyl 4 0 2,3 ,4, 6 tetra O acetyl a glucopyranosyl ss glucopyranoside To 27.4 g of 4 nitrophenyl 2,3,6 tri O acetyl 4 0 2,3,4,6 tetra O acetyl a glucopyranosyl ss glu copyranoside suspended in 150 ml of acetic acid was added 2.7 g of 10 palladium on charcoal catalyst in a Parr hydrogenation bottle, and this was hydrogenated on a Parr hydrogenator for 17 hours. The catalyst was filtered from the solution through diatomaceous earth and washed thoroughly with methanol. The solvents were evaporated in vacuo. The residue was dissolved in one liter of toluene and again evaporated. The residue was dissolved in methylene chloride and passed through a pad of magnesium silicate and the solvent was evaporated to yield the title compound as a light yellow oil.A 3.5 g portion of this was crystallized from methanol to yield 2.6 g of an off white crystal, m.p. 173 1750C. Example 38 N,N Bis 4 2,3,6 tri 0 acatyl 4 0 2,3,4,6 tetra O acetyl a D glucopyranosyl 8 D glucopyranosyl oxy jphenyl butanediamide To a stirred solution of 10 g of 4 aminophenyl 2,3,6 tri 0 acetyl 4 0 2,3,4,6 tetra 0 acetyl alpha galucopy ranosy1 D g1ucopyranoside in 100 ml of a dry mixture of pyridine acetonitrile 1 1 under argon was added a solution of 1.14 g of succinyl chloride in 10 ml of acetonitrile.This mixture was allowed to stir, under argon, for 18 hours.The solution was poured into 900 ml of water and stirred for 15 minutes. The oil was then separated and extracted into 500 ml of ethyl acetate and passed through a pad of hydrous magnesium silicate. Evaporation yielded 7.25 g of the title compound, which was chromatographed on 800 g of silica gel and eluted with ethyl acetate hexane. Fractions containing the desired product were combined and evaporated to 6.4 g of a white foam, alpha 26 D 45 2 0.64 , CHCl3 . Example 39 N,N Bis 4 4 0 alpha D galucopyranosyl ss D glucopyranosyloxy i phenyl j butanediamide A 3.0 g portion of N,N bis 4 2,3,6 tri O acetyl 4 0 2,3,4,6 tetra O acetyl a D glucopyranosyl ss gluco pyranosyloxy phenyl butanediamide was dissolved in a 0 C solution of 50 ml of methanol saturated with ammonia. The solution was allowed to stand at room temperature, under an inert atmosphere, for 18 hours, then was evaporated. The residue was crystallized from methanol water to yield 1.35 g of the title compound as a dihydrate, m.p. 190 2000C. Example 40 N,N Bis 4 4 0 alpha D glucopyranosyl ss D glucopyranosyloxy phenyl butanediamine A 3.79 g portion of N,N bis 4 2,3,6 tri O acetyl 4 0 2,3,4,6 tetra O acetyl a glucopyranosyl ss gluco pyranosyloxy phenyl butanediamide was added to 25 ml of tetrahydrofuran. This mixture was flushed with argon and cooled in an ice water bath. A 100 ml portion of 1M diborane in tetrahydrofuran was added at a rapid rate with stirring and upon completion, the cooling bath was removed.The reaction was stirred at ambient temperature overnight, then refluxed for 1 2 hour, cooled and the diborane decomposed by the addition of 100 ml of methanol. The resulting solid was collected, giving 640 mg of the desired intermediate as a white powder, m.p. 2850C dec. . Example 41 Tetradecasodium N,N bis 4 2,3,6 tri O sulfo 4 O 2,3,4, 6 tetra O sulfo a D glucopyranosyl D glucopyranosyloxy pbenyllbutanediamide Into a warm solution of 5.35 g of triethylaminesulfur trioxide complex and 4 g of 4A molecular sieves in 20 ml dry N,N dimethylacetamide was dissolved 1.0 g of N,N bis 4 4 O a D glucopyranosyl 3 D glucopyranosyloxyi phenyl butanediamide. The resulting solution was allowed to stand at 60 650C in an oil bath, under argon, for 17 hours. The mixture was filtered and the filtrate poured into 400 ml of acetone. After standing for one hour, the supernatant solution was decanted and the residual gum tetradecatriethylammonium salt was washed with three 50 ml portions of acetone. The gum was then dissolved in a solution composed of 2 g of anhydrous sodium acetate in 10 ml of water. This solution was added in a thin stream, with stirring, to 500 ml of absolute ethanol, stirred for 20 minutes and then allowed to stand for 2 hours. The supernatant was siphoned from the solid which was then collected on a filter and washed repeatedly with absolute ethanol and finally with ether. Vacuum drying at 400C provided 3.0 g of the desired product as an amorphous powder. To remove residual amounts of sodium sulfate the product was redissolved in 50 ml of water and mixed with 5 ml of 1M barium acetate solution. The solution was centrifuged at 3000 rpm for 30 minutes and the cloudy super natant was decanted and filtered through a 90S clarification filter, which in turn is washed with a small amount of water. The clear filtrate is passed through 100 g of activated Amberlitee CG 120 ion exchange resin Na form , packed into a 30 mm ID glass column. The sample was washed off the column with distilled water and fractions containing carbohydrate were pooled. The combined fractions are evaporated to 15 ml and the title compound was precipitated with 500 ml of hot ethanol.The solid was collected and dried in vacuo giving 2.3 g of white powder, a 26 140 5 0.27 , H20 . Example 42 Following the procedure of Example 7, N,N bis 4 2,3,6 ti 0 sulfo 4 0 2,3,4,6 tetra 0 sulfo alpha D gluco pyranosyl 8 D glucopyranosyloxyjphenyl butanediamine is converted to the corresponding tetradecasodium salt. Example 43 N,N Bis 4 2 ,3,4,6 tetra O aceeyl B gluco pyranosyl thio3phenyl3pentanediamide To a mixture of 3.0 g of 50 sodium hydride in oil dispersion in 40 ml of dry dimethoxyethane under argon was added dropwise a solution of 8.7 g of 4 aminothiophenol in 70 ml of dry dimethoxyethane. The mixture was stirred for 3.5 hours, then a solution of 25.5 g of a D bromoglucose tetraacetate in 70 ml of dry dimethoxyethane was added dropwise at a fast rate. The mixture was stirred overnight, filtered through diatomaceous earth and the filtrate evaporated to a glass. This glass was dissolved in 150 ml of dichloromethane, filtered through hydrous magnesium silicate, washed with one liter of dichloromethane, treated with charcoal and filtered through diatomaceous earth.The filtrate was evaporated to a glass which was dissolved in 150 ml of hot ether and then refrigerated overnight, giving 15.8 g of 4 aminophenylthio 2,3,4,6 tetra 0 acetyl ss D glucopyranoside. To a solution of 5.0 g of the above compound in 50 ml of dry pyridine acetonitrile 1 1 stirring under argon, was added dropwise a solution of 930 mg of glutaryl chloride in 3 ml of acetonitrile. This mixture was stirred for 2 hours, a small portion of glutaryl chloride was added, the mixture was allowed to stand overnight, then poured into 250 ml of water and stirred for 15 minutes. The resulting gum was extracted twice with chloroform, the extracts were combined, washed with 0.5 hydrochloric acid, dried, treated with charcoal and filtered through diatomaceous earth.The filtrate was evaporated to a glass which was dissolved in 100 ml of chloroform, filtered through hydrous magnesium silicate, washed with 600 ml of chloroform and evaporated, giving the desired intermediate as 4 g of a tan glass. Example 44 N,N Bis 4 ss glucopyranosyl thio phenyl pentanediamide To 4.0 g of N,N bis 4 2,3,4,6 tetra O acetyl 4 D glucopyranosyl thio phenyl pentanediamide was added 500 ml of ammonia saturated methanol at OOC. The solution was kept at OOC for 2 hours, then at ambient temperature overnight and taken to dryness in vacuo. The residue was triturated with 20 ml of absolute ethanol and the resulting solid was collected, giving 1.45 g of the desired intermediate as an amorphous solid. Example 45 Octasodium N,N bis 4 2,3,4,6 tetra O sulfo ss D glucopyranosyl thiolphenyl pentanediamide A 6.75 g portion of triethylamine sulfur trioxide complex was dissolved in 30 ml of dry N,N dimethylacetamide. A 6.75 g portion of 4A molecular sieves was added and the mixture was heated at 600C for 15 minutes. A 1.25 g portion of N,N bis 4 C D glucopyranosyl thio phenyli pentanediamide was added and the mixture was heated at 600C under argon for 4 hours, then cooled overnight, poured into 650 ml of acetone and refrigerated overnight. The resulting gum octatriethylammonium N,N bis 4 2,3,4,6 tetra O sulfo D glucopyranosyl thio phenyl pentanedi amide was separated, washed with acetone and added to 10 ml of water containing 1.5 g of sodium acetate.The mixture was filtered through diatomaceous earth and the filtrate added to 600 ml of absolute ethanol, stirred for 30 minutes and allowed to stand overnight. The solid was collected, washed with absolute ethanol, then ether and dried in vacuo, giving 1.57 g of the desired product. Example 46 1,4 Dioxo 1,4 butanediyl bis imino 4,1 phenylene bis 2,3,4 tri O acetyl l thio ss D glucopyranosid uronic acid , dimethyl ester To a mixture of 700 mg of 50 sodium hydride oil dispersion in 50 ml of dry dimethoxyethane, stirred under argon was added dropwise a solution of 3.0 g of sodium 4 aminothiophenol in 25 ml of dry dimethoxyethane. The mixture was stirred for 2 hours, then a solution of 4.8 g of methyl acetobromoglucuronate in 25 ml of dry dimethoxyethane was added. The mixture was stirred overnight, filtered through diatomaceous earth, washed with dimethoxyethane and taken to dryness. The residue was taken up in chloroform, filtered through hydrous magnesium silicate, washed with one liter of chloroform and taken to dryness, giving a syrup.This syrup was chromatographed on 600 g of silica gel in a nylon column, the column being divided into 36 equal segments. Segments 15 23 were combined, suspended in ethyl acetate, filtered free of silica gel, and taken to dryness in vacuo, giving a yellow glass which was crystallized from ether, giving 4 aminophenylthio 2,3,4 tri 0 ace tyl D glucopyranosiduronic acid, methyl ester as off white crystals. To a stirred solution of 2.0 g of the above compound in 20 ml of pyridine acetonitrile 1 1 under argon was added dropwise a solution of 365 mg of succinyl chloride in 3 ml of acetonitrile. The mixture was allowed to stand 4 hours and then added with stirring to 125 ml of water. The mixture was stirred 15 minutes, then the solid was collected, dried, dissolved in 50 ml of chloroform and filtered through hydrous magnesium silicate, washing with 600 ml of chloroform. The filtrate was evaporated to a white glass.The addition of methanol and chilling gave crystals which were washed with cold methanol, then ether and dried, giving 785 mg of the desired intermediate as white crystals, m.p. 2200C. Example 47 1,4 Dioxo 1,4 butanediyl bis imino 4,1 phenylene bis l thio ss D glucopyranosiduronic acid , dimethyl ester 1,4 Dioxo 1,4 butanediyl bis imino 4,1 phenyl ene bis 2,3,4 tri 0 acetyl 1 thio ss D glucopyranosiduronic acid , dimethyl ester may be converted to the desired intermediate essentially by the procedure of Example 2. Example 48 Hexasodium 1,4 dioxo 1,4 butanediyl bis imino 4,1 phenylene bis 2,3,4 tri O sulfo l thio ss D glucopyranosiduronic acid , dimethyl ester 1,4 Dioxo 1,4 butanediyl bis imino 4,1 phenyl ene bis 1 thio ss D glucopyranosiduronic acid , dimethyl ester may be converted to the desired product essentially by the procedure of Example 3. Example 49 1,5 Dioxo 1,5 pentanediyl bis imino 4,1 phenylene bis 2,3,4 tri O acetyl l thio ss glucopyrano siduronic acid , dimethyl ester To a solution of 2.0 g of 4 aminophenylthio 2,3,4 tri O acetyl D glucopyranosiduronic acid, methyl ester in 20 ml of pyridine acetonitrile 1 1 under argon, with swirling, was added a solution of 383 mg of glutaryl chloride in 3 ml of acetonitrile. The procedure of Example 1 was followed, giving 1.8 g of the desired intermediate as a cream colored foam. Example 50 1,5 Dioxo 1,5 pentanediyl bis imino 4,1 phenylene bis l thio ss glucopyranosiduronic acid To a solution of 1.7 g of 1,5 dioxo 1,5 pentenediyl bis imino 4,1 phenylena bis 2,3,4 trio 0 acetyl I thio B glucopyranosiduronic acid , dimethyl ester in 30 ml of methanol was added 1.74 ml of 5N sodium hydroxide with stirring, under an argon atmosphere. Stirring was continued for one hour, then 2.0 ml of 6N glacial acetic acid was added and the solution was taken to dryness. The residue was evaporated three times from toluene, giving a glass which was triturated with 150 ml of absolute ethanol, giving 1.29 g of the desired intermediate as an amorphous solid. Example 51 Octasodium 1,5 dioxo 1,5 pentanediyl bis imino 4,l phenylene bis 2,3,4 tri 0 sulfo l thio D glucopyranosiduronic acid A 5.18 g portion of triethylamine sulfur trioxide complex was reacted with 1.0 g of 1,5 dioxo 1,5 pentanediyl bis imino 4,1 phenylene bis 1 thio ss D glucopy ranosiduronic acid and then with sodium acetate as described in Example 3, giving 1.13 g of the desired product as a cream colored amorphous solid. Example 52 4 Aminophenyl 2,3,6 tri O acetyl 4 O 2,3,4,6 tet ra 0 acetyyl alpha D glucopyranosyl 1 thio ss D gluco pyranoside To a slurry of 0.6 g of hexane washed sodium hydride 50 oil dispersion in 50 ml of dry dimethoxyethane was added a solution of 1.7 g of 4 aminothiophenol in 25 ml of dry dimethoxyethane. The mixture was stirred for 1 2 hour, then 8.7 g of acetobromomaltose in 20 ml.of dimethoxyethane was added. This solution was stirred overnight, then refluxed for 7 hours. The reaction was filtered and the filtrate was extracted with 50 ml of 10 sodium carbonate and 50 ml of water. The organic layer was dried, concentrated to a solid which was purified ba chromatography, giving 4.1 g of the desired compound alpha 26n 440 CHCl3 . Example 53 N,N Bis 4 2,3,6 tri O acetyl 4 0 2,3,4,6 tetra O ace tyl crg gl ucopyranosyl 8 q gluco pyranosyl ithioiphenyl Jurea To a solution of 21.4 g of 4 aminophenyl 2,3,6 tri 0 acetyl 4 0 2,3,4,6 tetra 0 acetyl alpha D gluco pyranosyl 1 thio ss D glucopyranoside in 200 ml of toluene and 25 ml of pyridine there was added 5.53 ml of toluene containing 1.77 g of phosgene. This mixture was stirred for 18 hours, then concentrated, dissolved in dichloromethane, washed with water, then saline, dried and reconcentrated. This concentrate was purified by high performance liquid chromatography, giving 10.3 g of the desired intermediate. Example 54 N,N Bsi 4 4 0 alpha D glucopyra nosyl ss D glucopyranosyl thio phenyl urea A mixture of 17.3 g of N,N bis 4 2,3,6 tri O acetyl 4 0 2,3,4,6 tetra O acetyl a D glucopyranosyl ss D glucopyranosyl thio phenyljurea in 500 ml of methanol saturated with ammonia was stirred in an ice bath for 6 hours and then refrigerated overnight. The mixture was filtered through a sintered glass funnel and concentrated in vacuo to a foam. The foam was triturated with ethanol, filtered, washed with ethanol then ether and dried, giving 11.42 g of the desired intermediate. Example 55 Tetradecasodium N,N bis 4 2,3,6 tri 0 sul fo 4 0 2,3,4,6 tetra 0 sulfo alpha D gluco pyranosyl ss D glucopyranosyl thio phenyl urea A 72.0 g portion of triethylamine sulfur trioxide complex was dissolved in 350 ml. of dry N,N dimeth ylacetamide containing 72.0 g of 4A molecular sieves.This mixture was heated at 60 65 0C for 20 minutes. A 10.5 g portion of N,N bis 4 4 O a D glucopyranosyl ss D glucopyranosyl thio phenyl urea was added and the mixture was heated at 63 65 0C for 48 hours. The mixture was then cooled, filtered and the filtrate added to 4 liters of acetone and stirred giving a solid which is the tetradecatriethylammonium derivative of the title product. This solid was dissolved in 85 ml of water containing 15.6 g of sodium acetate, stirred for 20 minutes, filtered and the filtrate slowly added to 4 liters of absolute ethanol and stirred for 1 2 hour. The resulting solid was collected, washed with ethanol and dried giving 16.22 g of the desired product as a light tan solid. Example 56 Preparation of Compressed Tablet Ingredient mg. Tablet Active Compound 0.5 500 Dibasic Calcium Phosphate N.F. ........... qs Starch USP.............................. 40 Modified Starch......................... 10 Magnesium Stearate USP.................. 1 5 Example 57 Preparation of Compressed Tablet Sustained Action Ingredient mg. Tablet Active Compound as Aluminum 0.5 500 as acid Lake , Micronized equivalent Dibasic Calcium Phsophate N.F. .................. qs Alginic Acid.............................. 20 Starch USP................................ 35 Magnesium Stearate USP................... 1 10 Complement inhibitor plus aluminum sulfate yields aluminum complement inhibitor. Complement inhibitor content in aluminum lake ranges from 5 30 . Example 58 Preparation of Hard Shell Capsule Ingredient mg. Capsule Active Compound 0.5 500 Lactose, Spray Dried qs Magnesium Stearate 1 10 Example 59 Preparation of Oral Liquid Syrup Ingredient W v Active Compound 0.05 5 Liquid Sugar 75.0 Methyl Paraben USP 0.18 Propyl Paraben USP 0.02 Flavoring Agent qs Purified Water qs ad 100.0 Example 60 Preparation of Oral Liquid Elixir Ingredient W V Active Compound 0.05 5 Alcohol USP......... 12.5 Glycerin USP........ 45.0 Syrup USP........... 20.0 Flavoring Agent qs Purified Water qs ad 100.0 Example 61 Preparation of Oral Suspension Syrup Ingredient W v Active Compound as Aluminum 0.05 5 Lake, Micronized acid equivalent Polysorbate 80 USP...... 0.1Magnesium Aluminum Silicate, Colloidal 0.3Flavoring Agent....... qsMethyl Paraben USP.... 0.18Propyl Paraben USP.... 0.02Liquid Sugar.......... 75.0Purified Water qs ad.. 100.0 Example 62 Preparation of Injectable Solution Ingredient W V Active Compound 0.05 5 Benzyl Alcohol N.F. ...... 0.9 Water for Injection 100.0 Example 63 Preparation of Injectable Oil Ingredient W V Active Compound 0.05 5 Benzyl Alcohol 1.5 Sesame Oil qs ad............... 100.0 Example 64 Preparation of Intra Articular Product Ingredient AmountActive Compound 2 20 mg.NaCl physiological saline 0.9 Benzyl Alcohol 0.9 Sodium Carboxymethylcellulose 1 5 pH adjusted to 5.0 7.5Water for Injection qs ad...... 100 Example 65 Preparation of Injectable Depo Suspension Ingredient W V Active Compound 0.05 5 acid equivalent Polysorbate 80 USP..............0.2 Polyethylene Glycol 4000 USP 3.0 Sodium Chloride USP 0.8 Benzyl Alcohol N.F. .......... 0.9 HCl to pH 6 8............... qs Water for Injection qs ad... 100.0 Example 66 Preparation of Dental Paste Ingredient W V Active Compound 0.05 5Zinc Oxide............. 15Polyethylene Glycol 4000 USP 50Distilled Water qs..... 100 Example 67 Preparation of pental Ointment Ingredient W W Active Compound 0.05 5 Petrolatum, White USP qs...... 100 Example 68 Preparation of Dental Cream Ingredient W W Active Compound 0.05 5 Mineral Oil................... 50 Beeswax 15 Sorbitan Monostearate 2 Polyoxyethylene 20 Sorbitan Monostearate 3 Methyl Paraben USP............. 0.18 Propyl Paraben USP............. 0.02 Distilled Water qs............. 100 Example 69 Preparation of Topical Cream Ingredient W 2 Active Compound 0.05 5 Sodium Lauryl Sulfate 1 Propylene Glycol 12 Stearyl Alcohol 25 Petrolatum, White USP............ 25 Methyl Paraben USP............... 0.18 Propyl Paraben USP............... 0.02 Purified Water qs................ 100 Example 70 Preparation of Topical Ointment Ingredient W W Active Compound 0.05 5 Cholesterol 3 Stearyl Alcohol 3 White Wax....................... 8 PetrolaTUM, White USP qs........ 100 Example 71 Preparation of Spray Lotion Non aerosol Ingredient W W Active Compound 0.05 5 Isopropyl Myristate 20 Alcohol Denatured qs......... 100 Example 72 Preparation of Buccal Tablet Ingredient mg. Tablet Active Ingredient 3.25 6 x Sugar.......................... 290.60 Acacia 14.53 Soluble Starch..................... 14.53 F. D. C. Yellow No. 6 Dye 0.49 Magnesium Stearate 1.60 325.00 The final tablet will weigh about 325 mg. and may be compressed into buccal tablets in flat faced or any other tooling shape convenient for buccal adminsitration. Example 73 Preparation of Lozenge Ingredient g. Lozenge Active Ingredient 0.0140 Kompacte Sugar Sucrest Co. 0.7138 6 x Sugar........................... 0.4802 Sorbitol USP Crystalline 0.ld38 Flavor 0.0840 Magnesium Stearate 0.0021 Dye qs Stearic Acid........................ 0.0021 1.4000 The ingredients are compressed into 5 8 flat based lozenge tooling. Other shapes may also be utilized. The compounds of the present invention may be administered internally, e.g., orally, intra articularly or parenterally, to a warm blooded animal to inhibit complement in the body fluid of the animal, such inhibition being useful in the amelioration or prevention of those reactions dependent upon the function of complement, such as inflammatory process and cell membrane damage induced by antigen antibody complexes. A range of doses may be employed depending on the mode of administration, the condition being treated and the particular compound being used. For example, for intravenous or subcutaneous use from about 5 to about 50 mg kg day, or every six hours for more rapidly excreted salts, may be used.For intra articular use for large joints such as the knee, from about 2 to about 20 mg joint week may be used, with proportionally smaller doses for smaller joints. The dosage range is to be adjusted to provide optimum therapeutic response in the warm blooded animal being treated. In general, the amount of compound administered can vary over a wide range to provide from about 5 mg kg to about 100 mg kg of body weight of animal per day. The usual daily dosage for a 70 kg subject may vary from about 350 mg to about 3.5 g. Unit doses of the acid or salt can contain from about 0.5 mg to about 500 mg. The compounds of the present invention may also be administered topically in the form of ointments, creams, lotions and the like, suitable for the treatment of complement dependent dermatological disorders. Moreover, the compounds of the present invention may be administered in the form of dental pastes, ointments, buccal tablets and other compositions suitable for application periodontally for the treatment of periodontitis and related diseases of the oral cavity. In therapeutic use, the compounds of this invention may be administered in the form of conventional pharmaceutical compositions. Such compositions may be formulated so as to be suitable for oral or parenteral administration.The active ingredient may be combined in admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration, i.e., oral or parenteral. The compounds can be used in compositions such as tablets. Here, the principal active ingredient is mixed with conventional tabletting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate, gums, or similar materials as nontoxic pharmaceutically acceptable diluents or carriers. The tablets or pills of the novel compositions can be laminated or otherwise compounded to provide a dosage form affording the advantage of prolonged or delayed action or predetermined successive action of the enclosed medication.For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids or mixtures of polymeric acids with such materials as shellac, shellac and cetyl alcohol, cellulose acetate and the like. A particularly advantageous enteric coating comprises a styrene maleic acid copolymer together with known materials contributing to the enteric properties of the coating. The tablet or pill may be colored through the use of an appropriate nontoxic dye, so as to provide a pleasing appearance. The liquid forms in which the novel compositions of the present invention may be incorporated for administration include suitable flavored emulsions with edible oils, such as, cottonseed oil, sesame oil, coconut oil, peanut oil, and the like, as well as elixirs and similar pharmaceutical vehicles. Sterile suspensions or solutions can be prepared for parenteral use. Isotonic preparations containing suitable preservatives are also desirable for injection use. The term dosage form, as described herein, refers to physically discrete units suitable as unitary dosage for warm blooded animal subjects, each unit containing a predetermined quantity of active component calculated to produce the desired therapeutic effect in association with the required pharmaceutical diluent, carrier or vehicle. The specification for the novel dosage forms of this invention are indicated by characteristics of the active component and the particular therapeutic effect to be achieved or the limitations inherent in the art of compounding such an active component for therapeutic use in warm blooded animals as disclosed in this specification. Examples of suitable oral dosage forms in accord with this invention are tablets, capsules, pills, powder packets, granules, wafers, cachets, teaspoonfuls, dropperfuls, ampules, vials, segregated multiples of any of the foregoing and other forms as herein described. The complement inhibiting activity of the compounds of this invention has been demonstrated by one or more of the following identified tests i Test Code 026 C1 inhibitor This test measures the ability of activa ted human Cl to destroy fluid phase human C2 in the presence of C4 and appropriate dilutions oE the test compound.An active inhibitor protects C2 from C1 and C4 ii TestCode 035 C3 C9 inhibitor This test determines the ability of the late components of human complement C3 C9 to lyse EAC 142 in the presence of appropriate dilutions of the test compound. An active inhibitor protects EAC 142 from lysis by human C3 C9 iii Cap 50 Test Here, appropriate amounts of the test compound are added to a pool of guinea pig or human serum in vitro, after which the undiluted serum capillary tube assay of U.S. Patent No.3,876,376 is run. The concentration of compound inhibiting 50 is reported and iv Guinea Pig IntraperitonealTest GPIP Guinea pigs weighing about 300 g are dosed intraperitoneall i.p. with 200 mg kg of the test compound dissolved in saline and adjusted to pH 7 8. Approximately 0.4 ml blood samples, taken by orbital sinus puncture 2 hours and 6 hours after injections, are collected directly into centrifuge tubes 5 ml blood samples, taken by decapitation 24 hours after injection, are collected directly into beakers. The samples are allowed to clot, centrifuged, and the resultant sera are assayed for complement activity using the capillary complement assay.Percent inhibition is calculated by comparison with simultaneous controls. The results of the GPIP appear in TableIV together with results of Test Code 026, 035, and Cap 50.Table It shows that the principal compounds of the invention possess highly significant complement modulating activity in warm blooded animals. TABLE IVBiological Activities EMI55.1 SEP in SEP vitro SEP Activity SEP in SEP vitro SEP Activity tb SEP Guinea SEP Pig tb SEP SEP Inhibition tb SEP Cl SEP C Late SEP Guinea SEP Intraperitoneal tb SEP 026 SEP 035 SEP Pig SEP Human SEP Time SEP Houre tb Compound SEP Wells SEP Wells SEP Cap SEP 50 SEP Cap SEP 50 SEP 2 SEP 6 SEP 24 tb Tetradecasodium SEP N,N bis 4 2,3,6 tri SEP 9 SEP 1.5 SEP 153 SEP 180 SEP 87 SEP 71 SEP 44 tb 0 sulfo 4 o 2,3,4,6, tetra 0 sulfo dglucopyranosyl D glucopyranosylthio phenyl octanediamide tb Tetradecasodium SEP N,N bis 4 2,3,6 tri SEP 10.2 SEP 1.4 SEP 253 SEP 40 SEP 85 SEP 83 SEP 34 tb 0 sulfo 4 0 2,3,4,6 tetra 0 sulfo Dglucopyranosyl D glucopyranosylthio phenyl butanediamide tb Tetradecasodium SEP N,N bis 4 2,3,6, tri SEP 9.9 SEP 1.5 SEP 156 SEP 58 SEP 90 SEP 88 SEP 44 tb 0 sulfo 4 0 2,3,4,6 tetra 0 sulfo Dglucopyranosyl D glucopyranosylthio phenyl pentanediamide tb Tetradecasodium SEP N,N bis 4 2,3,6 tri SEP 10.5 SEP 1.0 SEP 56 SEP 94 SEP 90 SEP 85 SEP 76 tb 0 sulfo 4 0 2,3,4,6 tetra 0 sulfo Dglucopyranosyl D glucopyranosylthio phenyl hexanediamide tb TABLE IV continued EMI56.1 SEP in SEP vitro SEP Activity SEP in SEP vivo SEP Activity tb SEP Guinea SEP Pig tb SEP SEP Inhibition tb SEP Cl SEP C Late SEP Guinea SEP Intraperitoneal tb SEP 026 SEP 035 SEP Pig SEP Human SEP Time SEP Hours tb Compound SEP Wells SEP Wells SEP Cap SEP 50 SEP Cap SEP 50 SEP 2 SEP 6 SEP 24 tb Tetradecasodium SEP N,N bis 4 2,3,6 triO sulfo 4 O 2,3,4,6 tetra O sulfo alpha D SEP 10.7 SEP 1.0 SEP 183 SEP 95 SEP 87 SEP 87 SEP 50 tb glucopyranosyl ss D glucopyranosythio phenyl heptanediamide tb Tetradecasodium SEP N,N bis 4 2,3,6 triO sulfo 4 O 2,3,4,6 tetra O sulfo alpha D SEP 5.0 SEP 0.8 SEP 121 SEP 394 SEP 88 SEP 87 SEP 75 tb glucopyranosyl ss D glucopyranosythio phenyl decanediamide tb Tetradecasodium SEP N,N bis 4 2,3,6 triO sulfo 4 O 2,3,4,6 tetra O sulfo alpha D SEP 9.9 SEP 1.6 SEP 158 SEP 84 SEP 90 SEP 90 SEP 47 tb glucopyranosyl ss D glucopyranosythio phenyl propanediamide tb Tetradecasodium SEP N,N bis 4 2,3,6 triO sulfo 4 O 2,3,4,6 tetra O sulfo alpha D SEP 12 SEP 2.0 tb glucopyranosyl ss D glucopyranosythio phenyl pentanediamide tb TABLE IV continued EMI57.1 SEP in SEP vitro SEP Activity SEP in SEP vivo SEP Activity tb SEP Guinea SEP Pig tb SEP SEP Inhibition tb SEP Cl SEP C Late SEP Guinea SEP Intraperitoneal tb SEP 026 SEP 035 SEP Pig SEP Human SEP Time SEP Hours tb Compound SEP Wells SEP Wells SEP Cap SEP 50 SEP Cap SEP 50 SEP 2 SEP 6 SEP 24 tb Tetradecasodium SEP N,N bis 4 2,3,6 triO sulfo 4 O 2,3,4,6 tetra O sulfo alpha D SEP 7 SEP 3.0 tb glucopyranosyl ss D glucopyranosythio phenyl tetradecanediamide tb Tetradecasodium SEP N,N bis 4 2,3,6 triO sulfo 4 O 2,3,4,6 tetra O sulfo alpha D SEP 9.5 SEP 1.2 SEP 213 SEP 124 SEP 90 SEP 90 SEP 80 tb glucopyranosyl ss D glucopyranosythio phenyl ethanediamide tb TABLE IV continued EMI58.1 SEP Cl SEP C Late tb SEP 026 SEP 035 tb Compound SEP Wells SEP Wells tb Tetradecasodium SEP N,N bis 4 2,3,6 triO sulfo 4 O 2,3,4,6 tetra O sulfo alpha D SEP 11 SEP 1.0 tb glucopyranosyl ss D glucopyranosythio phenyl tetradecanediamide tb Tetradecasodium SEP N,N bis 4 2,3,6 triO sulfo 4 O 2,3,4,6 tetra O sulfo alpha D SEP 12 SEP 2.0 tb glucopyranosyl ss D glucopyranosythio phenyl tetradecanediamide tb Tetradecasodium SEP N,N bis 4 2,3,6 triO sulfo 4 O 2,3,4,6 tetra O sulfo alpha D SEP 7 tb glucopyranosyl ss D glucopyranosythio phenyl tetradecanediamide tb TABLE IV continued EMI59.1 SEP in SEP vitro SEP Activity SEP in SEP vivo SEP Activity tb SEP Guinea SEP Pig tb SEP Guinea SEP SEP Inhibition tb SEP Cl SEP C Late SEP Pig SEP Human SEP Intraperitoneal tb SEP 026 SEP 035 SEP Cap SEP Cap SEP Time SEP Hours tb Compound SEP Wells SEP Wells SEP 50 SEP 50 SEP 2 SEP 6 SEP 24 tb Tetradecasodium SEP N,N bis 4 2,3,6 triO sulfo 4 O 2,3,4,6 tetra O sulfo alpha D SEP 11 SEP 2 SEP 133 SEP 75 SEP 90 SEP 91 SEP 58 tb glucopyranosyl ss D glucopyranosythio phenyl urea tb Tests identified by code herein. Activity in wells, a serial dilution assay higher well number indicates higher activity.The serial dilutions are two fold.